as a therapeutic target for the treatment of IBS. Central administration of CRH and its related peptides, urocortin (Ucn) I−III, mimics the stress-induced colonic response as follows: (1) CRH, Ucn I, and Ucn II inhibit gastric emptying and suppress propagative contractions by activating CRH receptor 2 (CRHR2).
www.irjournal.org dition, CRH and CRHR2 have been implicated as inflammatory inducers in Clostridium difficile toxin A-induced enteritis. 8, 9 In trinitrobenzenesulfonic acid-induced colitis, centrally administered CRH reduced inflammation. 10 Inhibiting CRHR1 activity with a specific antagonist, antalarmin, suppressed endotoxin-induced inflammation, resulting in reduced inflammatory cytokine production.
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As a critical pathological component of gastrointestinal diseases, including IBD and colon cancer, angiogenesis facilitates disease progression by supplying essential nutrients and by promoting the recruitment of immune cells and the release of cytokines, chemokines, and matrix-degrading enzymes. 12 Regulators of angiogenesis, including vascular endothelial growth factor (VEGF), basic fibroblast growth factor , and interleukin-8, are potential targets for the treatment of numerous vascular diseases. Emerging evidence suggests that the CRH family is a novel angiogenic regulator in endogenous and inflammatory conditions. This review highlights the possible role of the CRH family in angiogenesis.
OVERVIEW OF THE CRH SYSTEM 1. CRH Ligands
To date, four members of the CRH family have been identified, including CRH, Ucn I, Ucn II (stresscopin-related peptide), and Ucn III (stresscopin). [13] [14] [15] CRH is a 41-amino acid peptide isolated from the ovine hypothalamus. Its primary structure is well conserved among mammalian species. 16 Three novel CRH-related peptides were characterized more recently. Ucn I, a 40-amino acid peptide isolated from the rat midbrain, and two 38-amino acid peptides, Ucn II and III, show 45%−18% homology, respectively, with rat/human CRH.
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CRH-deficient mice exhibited normal postnatal growth, fertility, and longevity despite marked glucocorticoid deficiency. 18 Fetal development, however, was profoundly affected by this deficiency; the progeny of homozygous CRHdeficient mice all died within the first 12 h after birth as a result of lung dysplasia, including marked hypercellularity, thickened alveolar septae, and a paucity of air spaces. In addition, although the pituitary gland appeared normal, marked atrophy of the zona fasciculata of the adrenal gland, the area primarily responsible for corticosterone production in mice, was observed. The adrenal stress response was impaired and sexually dimorphic, resulting in reduced production of corticosterone in male mice. These observations suggest that CRH plays a critical role during stress. 
CRH Receptors
CRH ligands bind to two highly homologous receptors, CRHR1 and CRHR2, which belong to the G-protein-coupled receptor family (Fig. 1) . 21 CRHR1 and CRHR2 bind differentially to each of the CRH family members. CRHR1 shows high affinity for CRH and Ucn I, but no appreciable affinity for Ucn II and Ucn III. CRHR2 binds with greater affinity to Ucn I, Ucn II, and Ucn III than to CRH. Extensive alternate splicing of CRHR1 and CRHR2 produces various isoforms: CRHR1α , CRHR2α , CRHR2β , and CRHR2γ . 22 In general, CRHR1 mediates the "fight-or-flight" stress response through the CRH-ACTH-glucocorticoid axis, whereas CRHR2 mediates stress-coping responses through Ucn II (stresscopin) and Ucn III (stresscopin-related peptide).
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CRHR1-deficient mice exhibited a marked decrease in the size of the zona fasciculata region of the adrenal gland and thus had a low plasma concentration of corticosterone. 24 Although basal ACTH secretion was normal in these mice, restraint stress did not increase circulating ACTH levels. The progeny born to homozygous mutant females developed lung dysplasia with alveolar collapse and emphysema and died within 2 days after birth. In utero corticosterone treatment rescued the phenotype. The mutant mice were less sensitive to anxiogenic-like stimuli, suggesting that CRHR1 is required for a normal anxiety response.
CRHR2-deficient mice showed increased anxiety-like behavior, and they were hypersensitive to the HPA axis-mediated stress response. 25 Although the food intake pattern and weight changes were normal, the mice exhibited increased anxiety, decreased appetite, and thus reduced food intake in response to food deprivation stress. Intravenous infusion of www.irjournal.org
Ucn did not reduce the mean arterial pressure in the mutant mice, but the nitric oxide-mediated vasodilation response in the peripheral vasculature was normal. Thus, these findings suggest that CRHR1 mutant mice show decreased anxiety-like behavior, and CRHR2 mutant mice show increased anxiety-like behavior.
CRH Binding Proteins
The biological activities of the CRH family are modulated by CRH-binding protein (CRH-BP) and a soluble splice variant of CRHR2α (sCRHR2α ). 26, 27 CRH-BP is a secreted glycoprotein that binds to CRH and Ucn I. sCRHR2α also binds to CRH and Ucn I and reduces their biological activity. Neither Ucn II nor Ucn III exhibits appreciable affinity for CRH-BP or sCRHR2α . Fig. 2 . Functional diversity of the corticotropin-releasing hormone (CRH) system in relation to angiogenesis. The CRH system has been implicated in various biological functions pertinent to the cardiovascular system, including angiogenesis, vasodilation, alteration of blood pressure, and cardioprotection. www.irjournal.org A FUNCTIONAL DIVERSITY OF THE CRH SYSTEM
CRH in Angiogenesis
A large body of evidence supports the idea that the CRH system regulates angiogenesis. The endogenous role of the CRH system in vascular development was first examined by Bale et al. 28 CRHR2 inhibited postnatal neovascularization, as evidenced by hypervascularization in CRHR2-deficient mice by postnatal day 21. The underlying mechanisms included inhibition of smooth muscle cell (SMC) proliferation, reduction of VEGF release from SMCs, and inhibition of in vitro angiogenesis in endothelial cells. Interestingly, the increased vascularity in CRHR2-deficient mice involved both capillaries and large vessels. Furthermore, hypervascularization did not occur during development but progressed from birth into adulthood. This finding suggests that CRH is a potential therapeutic target for vascular disease intervention, including the treatment of cancer and chronic inflammatory diseases. CRHR2 could affect vascular development through two mechanisms: nitric oxide (NO) production and hypoxia. 29 NO increases endothelial cell survival and thus regulates angiogenesis. 30 In addition, inhibition of NO production may increase VEGF production. Therefore, CRHR2-induced NO production might affect local VEGF levels, resulting in vessel formation. Hypoxia increases hypoxia inducible factor-1α , which in turn increases VEGF production. In hypertensive CRHR2-deficient mice, vasoconstricted vessels caused tissue hypoxia, which in turn promoted hypoxia inducible factor-1α and VEGF production.
CRH in Tumor Angiogenesis
Subsequent studies have investigated the role of the CRH system in tumor angiogenesis. In a mouse xenograft model, CRH-overexpressing epithelial tumor cells increased angiogenesis and tumor growth by stimulating endothelial chemotaxis, without a discernible effect on SMC migration. 31 Ucn inhibited the growth of hepatocellular carcinoma by suppressing angiogenesis via the activation of CRHR2. 32 In addition, Ucn/CRHR2 was implicated in human renal cell carcinoma, a hypervascularized tumor. In the epithelial cells and microvasculature within the tumor tissues, CRHR2 expression was almost completely lost, indicating that CRHR2/ Ucn might act as an endogenous inhibitor of angiogenesis and that disruption of CRHR2/Ucn might promote tumorigenesis. 33 In studies of prostate cancer, although Ucn expression did not differ in cancer and normal tissues, CRHR2 expression was detected in the vascular endothelial cells of normal prostate tissue, but not in prostate cancer tissue. 34 Thus, loss of CRHR2 expression in the prostate could contribute to cancer progression and increased neovascularization. Furthermore, Ucn II suppressed the growth of Lewis lung carcinoma cell tumors by directly inhibiting cell cycling and suppressing tumor vascularization. 35 
CRH in Inflammatory Vasculature
Peripheral vessel changes, including increased permeability and/or angiogenesis, are a major component of the inflammatory process. The CRH system modulates these events. For instance, CRH and Ucn triggered skin mast cell degranulation and increased vascular permeability, as shown by paw edema assays. 36, 37 By modulating peripheral vessels, Ucn inhibited paw edema with 6−7 times greater potency than CRH. 38 CRHR1 exerted vasoprotective effects during vascular inflammation: blockade of CRHR1 significantly increased the tumor necrosis factor-induced expression of vascular adhesion molecule-1 and E-selectin in human aortic endothelial cells. 39 Furthermore, our group concluded that CRHR1 and CRHR2 have opposing effects on intestinal angiogenesis because CRH/CRHR1 promoted endogenous and inflammatory vessel growth, whereas Ucn III/CRHR2 inhibited these responses. 
CRH in Cardiovascular Function
The CRH family is a potent regulator of cardiovascular function. Intracerebroventricular administration of CRH causes cardiovascular changes similar to stress-induced responses, such as elevation of blood pressure (mean arterial pressure) and heart rate. Systemic administration of CRH or Ucn I might oppose these CNS effects and thus decrease blood pressure by increasing vasodilation in specific vascular beds. 13, 40 In addition, intracerebroventricular injection of Ucn II and Ucn III increased mean arterial blood pressure and heart rate; the cardiovascular effects of Ucn II were weaker than those induced by Ucn III. 41 Furthermore,
Ucns were reported to have a protective effect in myocardial infarction and heart failure, possibly through the activation of CRHR2. 42 Ucn II and Ucn III protected cardiomyocytes from hypoxia and reduced infarct size by activating the antiapoptotic Erk1/2 pathway. 43 Ucn I inhibited reactive oxygen species production and thus protected endothelial cells from free radical damage. 44 www.irjournal.org CRHR2 is expressed in cardiac myocytes and the systemic vasculature. Peripheral vasodilation may activate CRHR2 in vascular endothelial cells and SMCs. CRHR2-null mice exhibited elevated mean arterial pressure and diastolic pressure when compared with wild-type mice, suggesting that changes in cardiac function and blood pressure are critically dependent on CRHR2.
45 CRHR2-deficient mice are hypertensive despite having increased blood vessel density; loss of the vasodilatory effect and an increased number of small resistance vessels may contribute to the hypertension. 25, 45 The mechanism by which the CRH system regulates vasodilation is not yet clear. Vasodilation may be mediated by the release of NO from the endothelium and the consequent activation of the guanylyl cyclase signaling pathway. 46 Alternatively, endothelium-independent relaxation may occur through activation of cAMP-dependent protein kinase A, which reduces the calcium sensitivity of contraction.
47

CONCLUSIONS
This review outlined the previously underappreciated role of the CRH system in the endogenous development of the vasculature and in inflammatory and tumor angiogenesis. Given this role, the CRH system may have a therapeutic application in the treatment of vascular diseases (Fig. 2 ). Animal and in vitro studies suggest that Ucns have cardioprotective effects, although solid clinical evidence is lacking. Unlike conventional angiogenic factors such as basic fibroblast growth factor and VEGF, the CRH family does not trigger angiogenesis in all settings. Like angiopoietin-1, a potent angiogenic factor in the skin, the CRH family does not stimulate corneal neovascularization, which suggests that the CRH family specifically affects certain vascular beds. 48 A recent preclinical study using a synthetic CRH, corticorelin acetate (CrA), showed that CrA significantly delayed tumor growth when administered as a single agent, possibly by inhibiting tumor angiogenesis. 49 Moreover, when administered in conjunction with bevacizumab, an anti-VEGF antibody, CrA improved therapeutic outcomes. Because on-going pre-clinical studies point toward the use of the CRH family members as anti-angiogenic agents, additional studies are warranted to establish the mechanistic basis for novel therapeutic approaches to the treatment vascular diseases.
